Market Research > Industries > Healthcare

Market Research: OTC Competitor Cost Structures
USA 2006

OTC Competitor Cost Structures USA 2006

Published October 2006

View PDF brochure

The seventh edition of Kline’s syndicated analysis of the profitability and cost structures of ten leading OTC drug companies in the United States. Company profiles included in this report features overviews of each company’s OTC business unit; an assessment of domestic OTC sales by product class; and an analysis of costs, expenses, and profitability by company and by product class. (Y617)

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 24 000 (twenty four thousand US Dollars)]

INTRODUCTION [US$ 0]

INDUSTRY ANALYSIS [US$ 12 000]

Table 3-1 ESTIMATED U.S. SALES AND RANKING FOR TEN LEADING NONPRESCRIPTION DRUG COMPANIES, 2004 AND 2005
Table 3 2 ESTIMATED U.S. SALES OF NONPRESCRIPTION DRUGS AND TOTAL SALES OF TEN LEADING COMPANIES, 2005
Table 3 3 ESTIMATED U.S. SALES OF BRANDED NONPRESCRIPTION DRUG PRODUCTS FOR NINE LEADING COMPANIES BY PRODUCT CLASS, 2005
Table 3 4 ESTIMATED U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CLASS AND CATEGORY, 2005 AND 2004
Table 3-7 COST STRUCTURE OF THE U.S. NONPRESCRIPTION DRUGS INDUSTRY, 2005
Table 3-8 COST OF GOODS SOLD FOR TEN LEADING NONPRESCRIPTION DRUG MANUFACTURERS IN THE UNITED STATES, 2005
Table 3-10 OTHER OPERATING EXPENSES FOR TEN LEADING U.S. NONPRESCRIPTION DRUG MANUFACTURERS, 2005
Table 3-11 ESTIMATED U.S. SALES OF COUGH AND COLD PREPARATIONS, 2004 AND 2005
Table 3-12 COST STRUCTURES FOR THE COUGH AND COLD PREPARATIONS PRODUCT CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-13 ESTIMATED U.S. SALES OF INTERNAL ANALGESICS, 2004 AND 2005
Table 3-14 COST STRUCTURES FOR THE INTERNAL ANALGESICS PRODUCT CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-15 ESTIMATED U.S. SALES OF TOPICAL PRODUCTS, 2004 AND 2005 2,084
Table 3-16 COST STRUCTURES FOR THE TOPICAL PRODUCT CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-17 ESTIMATED U.S. SALES OF NUTRITIONAL PRODUCTS, 2004 AND 2005
Table 3-18 COST STRUCTURES FOR THE NUTRITIONALS PRODUCT CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-20 COST STRUCTURES FOR THE DIGESTIVE PRODUCTS CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-21 ESTIMATED U.S. SALES OF ALLERGY, ASTHMA, AND SINUS PRODUCTS, 2004 AND 2005
Table 3-22 COST STRUCTURE FOR THE ALLERGY, ASTHMA, AND SINUS PRODUCTS CLASS IN THE UNITED STATES FOR SCHERING-PLOUGH, 2005
Table 3-23 ESTIMATED U.S. SALES OF FEMININE PRODUCTS, 2004 AND 2005
Table 3-24 COST STRUCTURES FOR THE FEMININE PRODUCTS CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3-26 COST STRUCTURES FOR THE OTHER PRODUCTS CLASS IN THE UNITED STATES BY COMPANY, 2005
Table 3 5 ESTIMATED U.S. SALES OF LEADING NONPRESCRIPTION DRUG COMPANIES BY PRODUCT CLASS, 2005
Table 3-9 MARKETING EXPENSES FOR TEN LEADING U.S. NONPRESCRIPTION DRUG MANUFACTURERS, 2005

COMPANY PROFILES [US$ 16 800]

BAYER [US$ 3 000]

Table 4A-1 BAYER GROUP’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4A-2 COST STRUCTURE OF BAYER’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4A-3 COST STRUCTURE OF BAYER’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

GLAXOSMITHKLINE [US$ 3 000]

Table 4B-1 GLAXOSMITHKLINE’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4B-2 COST STRUCTURE OF GLAXOSMITHKLINE’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4B-3 COST STRUCTURE OF GLAXOSMITHKLINE’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

JOHNSON & JOHNSON [US$ 3 000]

Table 4C-1 JOHNSON & JOHNSON’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4C-2 GROWTH RATES FOR JOHNSON & JOHNSON’S U.S. NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2004 TO 2005

Table 4C-3 COST STRUCTURE OF JOHNSON & JOHNSON’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4C-4 COST STRUCTURE OF JOHNSON & JOHNSON’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

JOHNSON & JOHNSON MERCK [US$ 3 000]

Table 4D-1 JOHNSON & JOHNSON–MERCK’S U.S. SALES OF NONPRESCRIPTION DRUGS BY BRAND, 2004 AND 2005

Table 4D-2 COST STRUCTURE OF JOHNSON & JOHNSON-MERCK’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

NOVARTIS [US$ 3 000]

Table 4E-1 NOVARTIS’ U.S. SALES OF NONPRESCRIPTION DRUGS, 2004 AND 2005

Table 4E-2 COST STRUCTURE OF NOVARTIS’ U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4E-3 COST STRUCTURE OF NOVARTIS’ U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

PERRIGO [US$ 3 000]

Table 4F-1 LIST OF PERRIGO’S NONPRESCRIPTION DRUGS AND NATIONAL BRAND EQUIVALENTS, 2005

Table 4F-2 COST STRUCTURE OF PERRIGO’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2006

Table 4F-3 COST STRUCTURE OF PERRIGO’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

PFIZER [US$ 3 000]

Table 4G-1 NONPRESCRIPTION DRUG BRANDS GAINED BY PFIZER THROUGH ACQUISITION OF PHARMACIA, 2002

Table 4G-2 PFIZER’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4G-3 COST STRUCTURE OF PFIZER’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4G-4 COST STRUCTURE OF PFIZER’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

PROCTER & GAMBLE [US$ 3 000]

Table 4H-3 COST STRUCTURE OF PROCTER & GAMBLE’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4H-4 COST STRUCTURE OF PROCTER & GAMBLE’S U.S. NONPRESCRIPTION DRUGS

SCHERING-PLOUGH [US$ 3 000]

Table 4I-1 SCHERING-PLOUGH’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4I-2 COST STRUCTURE OF SCHERING-PLOUGH’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4I-3 COST STRUCTURE OF SCHERING-PLOUGH’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

WYETH [US$ 3 000]

Table 4J-1 WYETH’S U.S. SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY AND BRAND, 2004 AND 2005

Table 4J-2 COST STRUCTURE OF WYETH’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT, 2005

Table 4J-3 COST STRUCTURE OF WYETH’S U.S. NONPRESCRIPTION DRUGS BUSINESS UNIT BY PRODUCT CLASS, 2005

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.